Research on the inhibition on Klebsiella pneumoniae clinical isolates by antimicrobial peptide human β defensin 3

doi:10.3969/j.issn.1673-8640.2014.11.024

›› 2014, Vol. 29 ›› Issue (11): 1184-1187.DOI: 10.3969/j.issn.1673-8640.2014.11.024

• Orignal Article • Previous Articles Next Articles

Research on the inhibition on Klebsiella pneumoniae clinical isolates by antimicrobial peptide human β defensin 3

ZHANG Lei¹, YIN Shuwei², ZHANG Ting², QI Xin², LÜ Huiying², LIN Ping¹

1. Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China;
2. Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

Received:2014-07-15 Online:2014-11-01 Published:2014-11-28
Contact: 林萍,联系电话:021-64387250。

Abstract

Abstract:

Objective　To analyze the inhibition effects of antimicrobial peptide human β defensin 3（hBD3） against Klebsiella pneumoniae clinical isolates. Methods　Antimicrobial peptide hBD3 was synthesized. The direct inhibition on 20 Klebsiella pneumoniae clinical isolates were detected by minimal inhibitory concentration（MIC） test， antibacterial activity test and the analysis on some important functional genes. The antimicrobial peptide was combined with amoxicillin， ceftazidime and ciprofloxacin for observing the effects on antibiotic 50% MIC（MIC50） and 90% MIC（MIC90）. Results　The MIC of hBD3 against Klebsiella pneumoniae clinical isolates was（22.3±6.6）μg/mL， the bactericidal activity was observed while hBD3 concentration was as high as 8 μg/mL. The hBD3 could improve the expression of ompC and reduce the expression of yojL.When 5 μg/mL hBD3 was added ， the MIC50 and MIC90 against Klebsiella pneumoniae clinical isolates of ceftazidime and ciprofloxacin were dropped down. Conclusions 　There is a considerable antibacterial activity of antimicrobial peptide hBD3 against Klebsiella pneumoniae clinical isolates. It could be used to inhibit Klebsiella pneumoniae infection combined with antibiotics.

Key words: Human &beta, defensin 3, Antimicrobial peptide, Antibacterial test

CLC Number:

R378

ZHANG Lei, YIN Shuwei, ZHANG Ting, QI Xin, LÜ Huiying, LIN Ping. Research on the inhibition on Klebsiella pneumoniae clinical isolates by antimicrobial peptide human β defensin 3[J]. , 2014, 29(11): 1184-1187.

References

[1] Vikrant S, Guleria RC. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing peritonitis in a patient on continuous ambulatory peritoneal dialysis[J]. Saudi J Kidney Dis Transpl,2014,25(4):888-889.
[2] Fischetti VA. Phage antibacterials make a comeback[J]. Nat Biotechnol,2001,19(8):734-735.
[3] Parisien A,Allain B,Zhang J,et al. Novel alternatives to antibiotics:bacteriophages,bacterial cell wall hydrolases,and antimicrobial peptides[J]. J Appl Microbiol,2008,104(1):1-13.
[4] Jiang Y,Yang D,Li W,et al. Antiviral activity of recombinant mouse β-defensin 3 against influenza A virus in vitro and in vivo[J]. Antivir Chem Chemother,2012,22(6):255-262.
[5] Lee JK,Chang SW,Perinpanayagam H,et al. Antibacterial efficacy of a human beta-defensin-3 peptide on multispecies biofilms[J]. J Endod,2013,39(12):1625-1629.
[6] Schibli DJ,Hunter HN,Aseyev V,et al. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus [J]. J Biol Chem,2002,277(10):8279-8289.
[7] Clifford RJ,MilillO M,Prestwood J,et al. Detection of bacterial 16S rRNA and identification of four clinically important bacteria by real-time PCR[J]. PLoS One,2012,7(11):e48558.
[8] Domenech-Sanchez A,Benedi VJ,Martinez-Martinez L,et al. Evaluation of differential gene expression in susceptible and resistant clinical isolates of Klebsiella pneumoniae by DNA microarray analysis[J]. Clin Microbiol Infect,2006,12(9):936-940.
[9] 孙杰,徐炜新,时建英,等. 肺炎克雷伯菌的耐药性和防耐药突变浓度的初步研究[J]. 检验医学,2013,28(10):878-881.
[10] Dhariwal AK,Tullu MS. Colistin:re-emergence of the 'forgotten' antimicrobial agent[J]. J Postgrad Med,2013,59(3):208-215.
[11] Li Q,Zhou Y,Dong K,et al. Potential therapeutic efficacy of a bactericidal-immunomodulatory fusion peptide against methicillin-resistant Staphylococcus aureus skin infection[J]. Appl Microbiol Biotechnol,2010,86(1):305-309.
[12] Gould IM,Cauda R,Esposito S,et al. Management of serious meticillin-resistant Staphylococcus aureus infections:what are the limits[J]. Int J Antimicrob Agents,2011,37(3):202-209.
[13] Rice LB. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria[J]. Cleve Clin J Med,2007,74(Suppl 4):S12-S20.
[14] Wang G,Li X,Wang Z. APD2:the updated antimicrobial peptide database and its application in peptide design[J]. Nucleic Acids Res,2009,37(Database issue):D933-D937.

Research on the inhibition on Klebsiella pneumoniae clinical isolates by antimicrobial peptide human β defensin 3

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics